Blog

Small Pharma Reports Fiscal Second Quarter 2023 Highlights

Oct 16 • 4 min read

Small Pharma Inc. (TSXV: DMT | OTCQB: DMTTF), a biotechnology company focused on short-acting psychedelic-assisted therapies for mental health conditions, has today published its financial results for the three and six months ended August 31, 2022. Financial Highlights (including post-period events): Cash on hand as of August 31, 2022, was $27.1 million. Cash is net…

Revive Therapeutics Announces Finalization of Amended Phase 3 COVID-19 Study Protocol to FDA

Oct 16 • 3 min read

Revive Therapeutics Ltd. (OTCQB: RVVTF | CSE: RVV | FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, announced today that it has finalized an amended protocol to the U.S. Food & Drug Administration for the Company’s Phase 3 clinical trial (the “Study”) (NCT04504734)…

Psychedelic Stock Market Update | September, 2022

Oct 14 • 2 min read

Although the Psychedelic Invest index had been performing well since the lows in May, September turned out to be a bad month for the market with the index down -9.02%. As you can see in the chart below, that’s because the large cap psychedelic stocks had a mixed performance in September. While some stocks such…

What Has Been Going On With MindMed Lately?

Oct 14 • 6 min read

MindMed ($MNMD) – the starry-eyed prospect in the psychedelic biotech space has recently turned into a soap opera starring Freeman Capital, angry retail investors, and piquing the interest of everyone interested in psychedelics. The last few months have been a rollercoaster for the company. Their management appears to remain calm as others are swiping on…

Algernon Pharmaceuticals Announces Dr. Rick Strassman author of “DMT: The Spirit Molecule” to Join CEO Christopher J. Moreau for Keynote Science Address at Wonderland Conference

Oct 14 • 4 min read

Algernon Pharmaceuticals Inc. (CSE: AGN | FRANKFURT: AGW0 | OTCQB: AGNPF) a clinical stage Canadian pharmaceutical development company, is pleased to announce that Dr. Rick Strassman, author of the book DMT: The Spirit Molecule and Algernon consultant, will be joining CEO Christopher J. Moreau for the Science Keynote Address at Wonderland, the world-leading event in the psychedelic…

Pages: 123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421422423424425426427428429430431432433434435436437438439440441442443444445446447448449450451452453454455456457458459460461462463464465466467468469470471472473474475476477478479480481482483484485486487488489490491492493494495496497498499500501502503504505506507508509510511512513514515516517518519520521522523524525526527528529530531532533534535536537538539540541542543